Matthew Luchini
Stock Analyst at BMO Capital
(1.11)
# 3,495
Out of 4,784 analysts
50
Total ratings
32.14%
Success rate
-8.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $10.39 | +188.74% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $4.46 | +4,160.09% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $24.27 | +184.30% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $2.91 | +3,473.88% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $1.75 | +3,042.86% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $7.59 | +1,230.70% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $637.36 | -1.15% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $327.87 | -62.18% | 2 | Nov 6, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | $1,120 | $4.08 | +27,350.98% | 11 | Nov 5, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $111.79 | -42.75% | 2 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $25.65 | -45.42% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.50 | +3,900.00% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $120 → $164 | $1.73 | +9,402.89% | 5 | Mar 8, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $10.39
Upside: +188.74%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $4.46
Upside: +4,160.09%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $24.27
Upside: +184.30%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $2.91
Upside: +3,473.88%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $1.75
Upside: +3,042.86%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $7.59
Upside: +1,230.70%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $637.36
Upside: -1.15%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $327.87
Upside: -62.18%
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: $1,120
Current: $4.08
Upside: +27,350.98%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $111.79
Upside: -42.75%
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $25.65
Upside: -45.42%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.50
Upside: +3,900.00%
Mar 8, 2018
Maintains: Market Perform
Price Target: $120 → $164
Current: $1.73
Upside: +9,402.89%